Skip to main content
Premium Trial:

Request an Annual Quote

Increasingly Personal

Premium

One of the recurring themes at the American Society of Clinical Oncology meeting earlier this month was that genetic information could personalize cancer treatments, reports the Wall Street Journal's Ron Winslow. "A pattern is developing at an accelerated pace where we are able to match genetic information about a tumor to a new agent and get results," says John Mendelsohn at MD Anderson Cancer Center. And, the Journal says, many drug companies are working on new therapies linked to certain genetic profiles: for example, Roche Holding and Daiichi Sankyot are working together to develop the skin cancer drug vemurafenib that inhibits a BRAF mutation that is found in more than half of patients with advance melanoma. However, Winslow adds that researchers stress that personalized treatments don't necessarily lead to cures.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.